Colon to Rectum

Gut. 2023;72:1093−100

Lopes EW, Chan SSM, Song M, Ludvigsson JF, Håkansson N, Lochhead P, Clark A, Burke KE, Ananthakrishnan AN, Cross AJ, Palli D, Bergmann MM, Richter JM, Chan AT, Olén O, Wolk A, Khalili H; EPIC-IBD investigators

Lifestyle factors for the prevention of inflammatory bowel disease


Objective: To estimate the proportion of cases of Crohn’s disease (CD) and ulcerative colitis (UC) that could be prevented by modifiable lifestyle factors.
Design: In a prospective cohort study of US adults from the Nurses’ Health Study (NHS; n = 72,290), NHSII (n = 93,909) and Health Professionals Follow-up Study (HPFS; n = 41,871), the authors created modifiable risk scores (MRS; 0−6) for CD and UC based on established lifestyle risk fac-tors, and healthy lifestyle scores (HLS; 0−9) derived from American healthy lifestyle recommendations. They calculated the population attributa-ble risk by comparing the incidence of CD and UC between low-risk (CD-MRS ≤ 1, UC-MRS ≤ 2, HLS ≥ 7) and high-risk groups. The findings were externally validated in 3 European cohorts: the Swedish Mammography Cohort (n = 37,275), Cohort of Swedish Men (n = 40,810) and European Prospective Investigation into Cancer and Nutrition (n = 404,144).
Results: Over 5,117,021 person-years of follow-up (NHS, HPFS: 1986−2016; NHSII: 1991−2017), the authors documented 346 CD and 456 UC cases. Adherence to a low MRS could have prevented 42.9% (95% confidence interval [CI]: 12.2−66.1%) of CD and 44.4% (95% CI: 9.0−69.8%) of UC cases. Similarly, adherence to a healthy lifestyle could have prevented 61.1% (95% CI: 16.8−84.9%) of CD and 42.2% (95% CI: 1.7−70.9%) of UC cases. In the validation cohorts, adherence to a low MRS and healthy lifestyle could have, respectively, prevented 43.9−51.2% and 48.8−60.4% of CD cases and 20.6−27.8% and 46.8−56.3% of UC cases.

Conclusions: Across 6 US and European cohorts, a substantial burden of inflammatory bowel diseases risk may be preventable through lifestyle modification.

H. Khalili, M.D., Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA,
E-Mail: hkhalili@partners.org

DOI: 10.1136/gutjnl-2022-328174

Back to overview

this could be of interest:

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomized, double-blind, controlled, phase 2, proof-of-concept trial

Lancet Gastroenterol Hepatol. 2023;8(4):307–20

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomized, double-blind, placebo-controlled, phase 3 studies

Lancet. 2023;401(10383):1159–71

More articles on the topic